Clinical trial
Natural Killer Cells in Allogeneic Cord Blood Transplantation
NCT01619761 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Natural Killer Cells in Allogeneic Cord Blood Transplantation
- Lead sponsor
- M.D. Anderson Cancer Center
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- May 3, 2013
- Completion date
- November 30, 2021
- Enrollment
- 13 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
accelerated phase chronic myelogenous leukemia, bcr-abl1 positive, acute biphenotypic leukemia, acute lymphoblastic leukemia in remission, acute myeloid leukemia in remission, chronic phase chronic myelogenous leukemia, bcr-abl1 positive, ds stage ii plasma cell myeloma, ds stage iii plasma cell myeloma, high grade b-cell lymphoma with myc and bcl2 or bcl6 rearrangements, iss stage ii plasma cell myeloma, iss stage iii plasma cell myeloma, myelodysplastic syndrome, recurrent acute lymphoblastic leukemia, recurrent acute myeloid leukemia, recurrent chronic lymphocytic leukemia, recurrent hodgkin lymphoma, recurrent non-hodgkin lymphoma, recurrent small lymphocytic lymphoma, refractory acute lymphoblastic leukemia, refractory chronic lymphocytic leukemia, refractory hodgkin lymphoma, refractory non-hodgkin lymphoma, refractory small lymphocytic lymphoma, secondary acute myeloid leukemia, therapy-related acute myeloid leukemia, therapy-related myelodysplastic syndrome